Cargando…

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis

OBJECTIVE: To characterize changes in myeloid and lymphoid innate immune cells in patients with relapsing-remitting multiple sclerosis (MS) during a 6-month follow-up after alemtuzumab treatment. METHODS: Circulating innate immune cells including myeloid cells and innate lymphoid cells (ILCs) were a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gross, Catharina C., Ahmetspahic, Diana, Ruck, Tobias, Schulte-Mecklenbeck, Andreas, Schwarte, Kathrin, Jörgens, Silke, Scheu, Stefanie, Windhagen, Susanne, Graefe, Bettina, Melzer, Nico, Klotz, Luisa, Arolt, Volker, Wiendl, Heinz, Meuth, Sven G., Alferink, Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063395/ https://www.ncbi.nlm.nih.gov/pubmed/27766281 http://dx.doi.org/10.1212/NXI.0000000000000289

Ejemplares similares

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Alterations of the Innate Immune System in Susceptibility and Resilience After Social Defeat Stress
por: Ambrée, Oliver, et al.
Publicado: (2018)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab
por: Strippel, Christine, et al.
Publicado: (2017)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses
por: Räuber, Saskia, et al.
Publicado: (2021)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cytotoxic CD8(+) T cells and CD138(+) plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies
por: Melzer, Nico, et al.
Publicado: (2012)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series
por: Strippel, Christine, et al.
Publicado: (2022)

Social Defeat Modulates T Helper Cell Percentages in Stress Susceptible and Resilient Mice
por: Ambrée, Oliver, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis
por: Thomas, Christian, et al.
Publicado: (2018)

The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity
por: Scheu, Stefanie, et al.
Publicado: (2017)

Classification of neurological diseases using multi-dimensional CSF analysis
por: Gross, Catharina C, et al.
Publicado: (2021)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Interferon β-Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity
por: Scheu, Stefanie, et al.
Publicado: (2019)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

Mitochondria, Microglia, and the Immune System—How Are They Linked in Affective Disorders?
por: Culmsee, Carsten, et al.
Publicado: (2019)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Impact of disease‐modifying therapies on humoral and cellular immune‐responses following SARS‐CoV‐2 vaccination in MS patients
por: Trümpelmann, Susan, et al.
Publicado: (2022)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid
por: Grauer, Oliver M, et al.
Publicado: (2015)

Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System
por: Ruland, Tillmann, et al.
Publicado: (2018)

Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system
por: Melzer, Nico, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_obvkkjg8cntgbne6br7rvefg6g